Preservation of β-Cell Function: The Key to Diabetes Prevention
The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Abstract
CONTEXT: The Centers for Disease Control and Prevention estimates that there are approximately 79,000,000 individuals in the United States with prediabetes [impaired glucose tolerance (IGT) and/or impaired fasting glucose] and that approximately 40-50% will progress to type 2 diabetes mellitus (T2DM) during their lifetime. Therefore, treatment of high-risk IGT individuals to prevent T2DM has important medical, economic, social, and human implications. Individuals in the upper tertile of IGT are maximally/near-maximally insulin resistant, have lost 70-80% of their β-cell function, and have approximately a 10% incidence of diabetic retinopathy. Therefore, preservation of the remaining 20-30% of β-cell function is critical to prevent future development of T2DM. EVIDENCE ACQUISITION: We searched MEDLINE from 2000 to the present to identify placebo-controlled trials in which individuals with IGT received pharmacological therapy to prevent progression to diabetes. EVIDENCE SYNTHESIS: Lifestyle modification reduces IGT conversion to T2DM, but it is difficult to implement and maintain. Moreover, 40-50% of IGT subjects progress to T2DM despite weight loss. In contrast, pharmacological intervention with medications that reverse known pathophysiological abnormalities (β-cell dysfunction and insulin resistance) uniformly prevents IGT progression to T2DM. Thiazolidinediones reduce IGT conversion to diabetes by approximately 50-70%. Metformin in the U.S. Diabetes Prevention Program reduced the development of T2DM by 31% and has been recommended by the American Diabetes Association. Because glucagon-like peptide-1 analogs augment insulin secretion, preserve β-cell function, and promote weight loss, they may be efficacious in preventing IGT progression to T2DM. CONCLUSION: Pharmacological intervention with a variety of agents (thiazolidinediones, metformin, acarbose, glucagon-like peptide-1 analogs) consistently reduces the rate of conversion of IGT to T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fasting plasma glucose values are determined by endogenous glucose production (EGP) that is mostly dependent on the liver.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The product of EGP and fasting insulin is used as a marker of hepatic insulin resistance and it shows a relatively strong relationship with fasting glycaemia.38,39,45”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“Both IFG and IGT subjects present with insulin resistance, however the site of insulin resistance is different: High hepatic insulin resistance is a typical finding in IFG with almost normal values in skeletal muscle.38,39,45 In IGT, the main site of insulin resistance is the muscle with only modest changes in liver insulin sensitivity.37,38”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The primary aim of lifestyle interventions is to prevent or delay the development of type 2 diabetes and its complications13,45 by targeting obesity and physical inactivity, the two most important modifiable risk factors of diabetes development.3,25”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
In the citing paper
“The glitazones, such as troglitazone, rosiglitazone and pioglitazone, act through the PPAR-γ receptor by increasing hepatic and peripheral insulin sensitivity and preserving insulin secretion.45,95”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [45]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Cited by
Items 101–200 of 200
Spiegel, A. M., & Hawkins, M. A. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1054 · Cited by 25
Pilot Study of Impact of a Pedal Desk on Postprandial Responses in Sedentary Workers
Han, H., Lim, J., Viskochil, R. H., Aguiar, E. J., Tudor‐Locke, C., & Chipkin, S. R. (2018) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001679 · Cited by 25
“, resistance), thus represents a key component of diabetes prevention (27).”
Hage, C., Brismar, K., Efendic, S., Lundman, P., Rydén, L., & Mellbin, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12032 · Cited by 22
Gayathri, R., Abirami, K., Kalpana, N., Manasa, V. S., Sudha, V., Shobana, S., Jeevan, R. G., Kavitha, V., Parkavi, K., Anjana, R. M., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1055923 · Cited by 24
Murro, E. D., Giuseppe, G. D., Soldovieri, L., Moffa, S., Improta, I., Capece, U., Nista, E. C., Cinti, F., Ciccarelli, G., Brunetti, M., et al. (2023) · Nutrients · doi:10.3390/nu15194202 · Cited by 27
“The preservation of residual β -cell function in individuals with obesity and IGT—who have already lost up to 50–70% of β -cell function—is an effective strategy to prevent T2DM [26,27].”
BackgroundMoreno, Ó., Reyes‐García, R., Muñoz‐Torres, M., Merino, E., Boix, V., Reus, S., Giner, L., Alfayate, R., García-Fontana, B., Sánchez–Payá, J., et al. (2018) · Clinical Endocrinology · doi:10.1111/cen.13800 · Cited by 21
Yokoyama, H. (2011) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph8073019 · Cited by 22
“In that the rest of the pancreatic β-cells must contribute to the prevention of the development of diabetes [46], it is fully conceivable that this effect of ethanol contributes to the prevention of development of diabetes.”
BackgroundExercise improves metformin 72-h glucose control by reducing the frequency of hyperglycemic peaks
ORTEGA, J. F., Morales‐Palomo, F., Ramírez-Jiménez, M., Moreno‐Cabañas, A., & Mora‐Rodríguez, R. (2020) · Acta Diabetologica · doi:10.1007/s00592-020-01488-7 · Cited by 23
“T2DM is the final stage of an initial insulin resistance state which has been labeled prediabetes [3].”
BackgroundRoles of β-Cell Hypoxia in the Progression of Type 2 Diabetes
Yamagata, K., Tsuyama, T., & Sato, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084186 · Cited by 22
“The genetic background causes insulin resistance and β -cell dysfunction, while being overweight and physical inactivity exacerbates these metabolic abnormalities [2–4].”
BackgroundJurczak, M. J., Saini, S., Ioja, S., Costa, D. K., Udeh, N., Zhao, X., Whaley, J. M., & Kibbey, R. G. (2018) · Islets · doi:10.1080/19382014.2018.1503027 · Cited by 19
“Not surprisingly, improved glycemic control either through diet, exercise or pharmacological intervention is associated with sustained pancreatic β-cell function.(11) Unfortunately, life-style interventions and the existing pharmacopeia of glucose lowering agents are ineffective for the maintenance of long-term glycem…”
BackgroundThe glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice
Qiu, Y., Shen, L., Fu, L., Yang, J., Cui, C., Li, T., Li, X., Fu, C., Gao, X., Wang, W., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05095-7 · Cited by 19
When does diabetes start? Early detection and intervention in type 2 diabetes mellitus
Peralta, F. G., Abreu, C., Cos, X., & Gómez‐Huelgas, R. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.12.004 · Cited by 26
The role of incretin-based therapies in prediabetes: A review
Ahmadieh, H., & Azar, S. T. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.02.005 · Cited by 24
Varvel, S. A., Vörös, S., Thiselton, D. L., Pottala, J. V., Dall, T., Warnick, G. R., McConnell, J. P., Ghaedi, L., Sasinowski, M., & Graham, T. E. (2014) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-014-9577-1 · Cited by 20
Choice of early treatment regimen and impact on β-cell preservation in type 2 diabetes
Mudaliar, S. R. D. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12154 · Cited by 19
Alogliptin benzoate for management of type 2 diabetes
Saisho, Y. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s68564 · Cited by 24
One-Hour Plasma Glucose Predicts the Progression From Normal Glucose Tolerance to Prediabetes
Abdul‐Ghani, M. A., Abu‐Farha, M., Abdul‐Ghani, T., Chavez-Velazquez, A., Merovci, A., DeFronzo, R. A., Al-Ajmi, F. A., Stern, M. P., & Al‐Mulla, F. (2025) · Diabetes Care · doi:10.2337/dc24-2832 · Cited by 18
Self-citationHigh-Intensity Exercise Training for the Prevention of Type 2 Diabetes Mellitus
Rynders, C. A., & WELTMAN, A. L. (2014) · The Physician and Sportsmedicine · doi:10.3810/psm.2014.02.2042 · Cited by 20
Tjandrawinata, R. R., Manaf, A., Malinda, D., & Susanto, L. W. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s97568 · Cited by 19
Myokine Regulation of Insulin Secretion: Impact of Inflammation and Type 2 Diabetes
Ryan, A., Ciaraldi, T. P., & Henry, R. R. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2019.01608 · Cited by 16
“However, since preserving β-cell function is also crucial to preventing diabetes (DeFronzo and Abdul-Ghani, 2011), it is critically important to understand how insulin resistant fat and muscle can contribute to β-cell failure and, conversely, how “healthy” fat and muscle may help preserve normal…”
BackgroundEffect of a family and interdisciplinary intervention to prevent T2D: randomized clinical trial
Vargas‐Ortiz, K., Lira-Mendiola, G., Navarro, C. M. G., Estrada, K. P., Angulo-Romero, F., Hernández-Márquez, J. M., Villa-Martínez, A., González-Mena, J. N., Macías-Cervantes, M. H., Reyes‐Escogido, M. D. L., et al. (2020) · BMC Public Health · doi:10.1186/s12889-020-8203-1 · Cited by 19
Jiang, L., Gao, C., Yan, P., Chen, P., Jiang, C., Xu, Y., & Chen, M. (2022) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2020.1814239 · Cited by 16
“Insulin resistance showed obviously negative influence on women ’ s reproductive health, menstrual changes, impaired fertility and sexual dysfunction etc. Insulin sensitivity could be improved by weight loss, increased physical activity, and use of medications [24 – 26].”
RetractedHuang, L., Jiang, X., Gong, L., & Xing, D. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25133 · Cited by 16
Wang, Y., Liu, S., Ying, L., Zhang, K., Li, H., Liang, N., Xiao, L., & Luo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910534 · Cited by 18
“Pio-neering studies indicate that at the onset of T2DM, β -cell function is already diminished to 50–80% of normal capacity [3,4].”
BackgroundSánchez, M., Sánchez, E., Bermúdez-López, M., Torres, G., Farràs-Sallés, C., Pamplona, R., Castro-Boqué, E., Valdivielso, J. M., Purroy, F. F., Martínez‐Alonso, M., et al. (2021) · Nutrients · doi:10.3390/nu13031002 · Cited by 15
“It is clear that subjects with this metabolic condition are estimated to have a 40% to 50% risk of developing type 2 diabetes [2].”
BackgroundTouaibia, M., St‐Cœur, P., Duff, P., Faye, D. C., & Pichaud, N. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174627 · Cited by 16
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“…lowers fasting plasma glucose and HbA1c in people with type 2 diabetes mellitus through reducing hepatic glucose production and enhancing insulin sensitivity, the data supporting its role in directly enhancing insulin secretion or signi fi cantly preserving b -cell function are not robust 149 .”
BackgroundCedó, L., Castell‐Auví, A., Pallarès, V., Ubaida‐Mohien, C., Baiges, I., Blay, M., Ardèvol, A., & Pinent, M. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.06.042 · Cited by 14
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats
Cummings, B. P., Bettaieb, A., Graham, J. L., Stanhope, K. L., Haj, F. G., & Havel, P. J. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0601 · Cited by 14
Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective
Saisho, Y. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.s1-008 · Cited by 18
“Beta cell failure in T2DM emphasizes the importance of preservation or recovery of beta cell functional mass as a treatment strategy for T2DM [4].”
BackgroundPathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_8 · Cited by 16
Self-citationThe Early Diabetes Intervention Program – is early actually late?
Bergman, M. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2563 · Cited by 14
“remaining well above the fasting level [17].”
BackgroundMoreno, Ó., Portilla, J., Escoín, C., Alfayate, R., Reus, S., Merino, E., Boix, V., Bernabéu, Á., Giner, L., Mauri, M. F., et al. (2013) · HIV Medicine · doi:10.1111/hiv.12042 · Cited by 14
Chen, X., Ding, J., Shi, Z., Bai, K., Shi, S., & Tian, Q. (2024) · BMC Public Health · doi:10.1186/s12889-024-18823-0 · Cited by 14
“From the perspective of community-based primary health care and primary prevention of CVD, the primary aim is to target two risk factors, obesity and physical inactivity, after identifying high-risk groups [40, 41].”
BackgroundEdelman, S. V., Ng‐Mak, D., Fusco, M., Ashton, D. W., Okerson, T. E., Liu, Q., Jin, J., & Dixon, J. B. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12313 · Cited by 14
Koltes, J. E., Arora, I., Gupta, R., Nguyen, D. C., Schaid, M. D., Kim, J., Kimple, M. E., & Bhatnagar, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-46219-3 · Cited by 12
¿Cuándo empieza la diabetes? Detección e intervención tempranas en diabetes mellitus tipo 2
Peralta, F. G., Abreu, C., Cos, X., & Gómez‐Huelgas, R. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.12.003 · Cited by 29
Khan, A. H. K. Y., Zakaria, N. F., Abidin, M. A. Z., & Kamaruddin, N. A. (2021) · Medicine · doi:10.1097/md.0000000000026729 · Cited by 13
Kirkpatrick, C. F., Liday, C., & Maki, K. C. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00838-8 · Cited by 12
Correlation of serum homocysteine and previous history of gestational diabetes mellitus
Alatab, S., Fakhrzadeh, H., Sharifi, F., Mirarefin, M., Badamchizadeh, Z., Ghaderpanahi, M., Hossein‐Nezhad, A., & Larijani, B. A. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-34 · Cited by 13
“Previous studies showed that impaired insulin secretion is the key in conversion from normal glucose tolerance to impaired glucose tolerance and finally diabetes [12,13].”
BackgroundRichter, B., Hemmingsen, B., Metzendorf, M., & Takwoingi, Y. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012661 · Cited by 15
Göbl, C. S., Bozkurt, L., Mittlböck, M., Leutner, M., Yarragudi, R., Tura, A., Pacini, G., & Kautzky‐Willer, A. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00059.2015 · Cited by 13
Mortality in relation to diabetes remission in Swedish Obese Subjects – a prospective cohort study
Carlsson, L. M. S., Carlsson, B., Jacobson, P., Karlsson, C., Andersson‐Assarsson, J. C., Kristensson, F. M., Ahlin, S., Svensson, P., Taube, M., Näslund, I., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001807 · Cited by 12
“Insulin production is already impaired during the prediabetic phase and is often reduced by up to 80% at the time of T2D diagnosis, re fl ecting the progressive nature of T2D [17] .”
BackgroundDietary Interventions and Type 2 Diabetes in Youth: a Fresh Look at the Evidence
Perkison, W. B., Adekanye, J. A., & Otto, M. C. D. O. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0241-2 · Cited by 13
Influencia étnica en la prevalencia de síndrome metabólico en población pediátrica obesa
Romero, P. E., Gutiérrez, B., Gil, N. Á., Martín-Frías, M., Alonso‐Blanco, C., & Castellanos, R. B. (2012) · Anales de Pediatría · doi:10.1016/j.anpedi.2012.04.010 · Cited by 16
Fang, F. S., Cheng, X. L., Gong, Y., Wang, L. C., Li, C., Li, J., Tian, H., & Li, C. L. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.918030 · Cited by 11
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
Bethel, M. A., Xu, W., & Theodorakis, M. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12401 · Cited by 13
“Similarly, metformin has conclusively been shown not to prevent the gradual decline in β-cell function, a hallmark of type 2 diabetes progression [11,12].”
BackgroundPrevention of type 2 diabetes: what is the right target population?
Williamson, D. A. (2018) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2018.1535896 · Cited by 13
“Abdul-Ghani [24] came to a similar conclusion: preservation of β cell function is the key to T2D prevention.”
BackgroundInfluentialBelhayara, M. I., Mellouk, Z., Hamdaoui, M. S., Bachaoui, M., Khéroua, O., & Malaisse, W. J. (2020) · Nutrients · doi:10.3390/nu12030727 · Cited by 13
Schaefer, A. L., Ominski, K., Thompson, S., Crow, G. H., Bench, C., Colyn, J. J., Rodas‐González, A., Maharjan, D., Bollum, R., Cook, N. J., et al. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00843 · Cited by 11
Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence
Papaetis, G. S. (2019) · Current Diabetes Reviews · doi:10.2174/1573399816666191230113446 · Cited by 11
Pathogenesis of Type 2 Diabetes Mellitus
DeFronzo, R. A. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_8-1 · Cited by 13
Self-citationRisk factors of diabetes in North Indians with metabolic syndrome
Pratyush, D. D., Tiwari, S., Singh, S., & Singh, S. K. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.032 · Cited by 10
“IR has been shown as an underlying feature of MetS, pre-diabetes and diabetes [1,6,20].”
BackgroundResultKhan, A. H. K. Y., Zakaria, N. F., Abidin, M. A. Z., Lim, C. T. S., & Kamaruddin, N. A. (2020) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.035.01.12 · Cited by 12
Das, U. N. (2014) · Medical Science Monitor · doi:10.12659/msm.890698 · Cited by 12
Collier, J. J., Batdorf, H. M., Merrifield, K. L., Martin, T. M., White, U. A., Ravussin, É., Burk, D. H., Cooley, C. R., Karlstad, M. D., & Burke, S. J. (2021) · Biomedicines · doi:10.3390/biomedicines9091189 · Cited by 12
“Indeed, the power of TZDs to prevent progression to T2D was revealed in several clinical trials, even outperforming lifestyle interventions [11,12].”
BackgroundRecent advances of macroporous hydrogel microparticles: Fabrication and applications
Liu, Y., Ling, S., Chen, Z., & Xu, J. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.161435 · Cited by 12
Li, T., Cao, C., Xuan, X., Liu, W., Xiao, X., & Wei, C. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01518-9 · Cited by 9
“Although there are no published studies on Cre/BW ratio and progression from pre-diabetes to diabetes, it is clear that insulin resistance is strongly associated with progression from pre-diabetes to diabetes [8, 42, 43].”
BackgroundBarbosa, H. C. L., Drynda, R., Liu, B., de Ledesma, A. M. R., Malicet, C., Iovanna, J., Jones, P. M., Muller, D. S., & Persaud, S. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.01.013 · Cited by 10
“Hyperglycaemia is the main feature of type 2 diabetes (T2D), which occurs as a consequence of defective insulin action in peripheral tissues in combination with impaired insulin secretion from islet beta cells [2,3].”
BackgroundCummings, B. P., Graham, J. L., Stanhope, K. L., Chouinard, M. L., & Havel, P. J. (2013) · Obesity Surgery · doi:10.1007/s11695-013-1076-y · Cited by 11
Iskandar, S., Migahid, A., Kamal, D. T., Megahed, O., DeFronzo, R. A., Zirie, M. A., Jayyousi, A., Jaidah, M. A., & Abdul‐Ghani, M. A. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0412-1 · Cited by 15
Self-citationFederici, M. O., Gentilella, R., Corcos, A., Torre, E., & Genovese, S. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3434 · Cited by 8
Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
Ahn, C. H., Oh, T. J., Min, S. H., & Cho, Y. M. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.103 · Cited by 10
“Since chronic hyperglycemia itself impairs β-cell function [12], pharmacologic interventions to reduce hyperglycemia may improve β-cell function and restore β-cell glucose sensitivity [13].”
BackgroundTaheri, N., Aminorroaya, A., Ismail‐Beigi, F., & Amini, M. (2012) · Endocrine Practice · doi:10.4158/ep12057.or · Cited by 8
Cheung, J. T. K., Yang, A., Wu, H., Lau, E. S. H., Lui, J. N. M., Kong, A. P. S., Ronald, C. W., Luk, A. O. Y., Chow, E., & Chan, J. C. N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15662 · Cited by 7
“39 By intensifying treatment at a lower HbA1c threshold, we could avoid a precipitous fall in HbA1c, as shown by the graded relationship between HVS and HbA1c threshold value in our study.”
β-cell preservation and regeneration for diabetes treatment: where are we now?
Karadimos, M., Kapoor, A., Khattabi, I. E., & Sharma, A. (2012) · Diabetes Management · doi:10.2217/dmt.12.21 · Cited by 10
Early detection of metabolic dysregulation using water T2 analysis of biobanked samples
Mishra, I., Jones, C., Patel, V., Deodhar, S., & Cistola, D. P. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s180655 · Cited by 7
Rajabi‐Naeeni, M., Dolatian, M., Qorbani, M., & Vaezi, A. A. (2019) · Trials · doi:10.1186/s13063-019-3948-5 · Cited by 8
Liu, J., Yu, D., Xu, M., Feng, R., Sun, Y., Yin, X., Lai, H., Wang, C., & Liu, J. (2021) · Open Medicine · doi:10.1515/med-2021-0376 · Cited by 7
“T2DM patients have lost 50% of β-cell function at the time of diagnosis [24], and this value gradually increases with longer disease duration [25].”
BackgroundPancreatic β-cell Dysfunction and Diabetes
Iida, H., & Watada, H. (2025) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj25-0001-r · Cited by 12
“No therapies currently restore functional β-cell mass. Reducing β-cell burden is the most effective strategy for preserving β-cell mass, so diabetes management should focus on alleviating β-cell stress 52, 53 ) .”
Metformin in Prevention of Type 2 Diabetes.
Snehalatha, C., Susairaj, P., Nanditha, A., Raghavan, A., Satheesh, K., & Ramachandran, A. (2018) · PubMed · Cited by 6
Bariatric surgery normalizes diabetes risk index by one month post-operation
Sinatra, V. J., Lin, B., Parikh, M., Berger, J. S., Fisher, E. A. A., & Heffron, S. P. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-02002-x · Cited by 6
“DRI provides an evaluation of insulin resistance independent of glycemic status or adiposity—–making it ideal for those with fluctuating body weight, leaner body habitus and overall subtle progression of insulin resistance—those who may have deceptively normal glucose and insulin parameters but with initial loss of pa…”
BackgroundIwata, T., Cowley, T. J., Sloma, M., Ji, Y., Kim, H., Qi, L., & Lee, S. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078841 · Cited by 8
“In type 1 diabetes, pancreatic b-cells are selectively destroyed resulting in reduced b-cell mass, while in type 2 diabetes, loss of insulin-secretory ability as well as b-cell apoptosis lead to defects in glucose homeostasis [1,2].”
BackgroundPrediabetes in Obese Adolescents
Dingle, E., & Brar, P. C. (2016) · Clinical Pediatrics · doi:10.1177/0009922816681138 · Cited by 6
Heianza, Y., & Qi, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802928-2.00029-1 · Cited by 6
Effects of Gynura bicolor on Glycemic Control and Antioxidant Ability in Prediabetes
Hsia, C., Tung, Y., Yeh, Y., & Chien, Y. (2021) · Applied Sciences · doi:10.3390/app11115066 · Cited by 4
“Individuals with both IFG and IGT have more severe dysglycemic condition and are especially at high-risk for type 2 diabetes [2].”
BackgroundHigh bicarbonate concentration increases glucose-induced insulin secretion in pancreatic β-cells
Zhang, Y.-C., Xiong, F., Wang, Y., Shen, H., Zhao, R., Li, S., Lü, J., & Yang, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.12.015 · Cited by 7
Carlsson, L. M. S., Carlsson, B., Jacobson, P., Andersson‐Assarsson, J. C., Karlsson, C., Kristensson, F. M., Ahlin, S., Näslund, I., Karason, K., Svensson, P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16010 · Cited by 6
“30,31 Indeed, individuals in the current report who developed diabetes exhibited more impaired metabolic health at baseline compared to those who remained diabetes-free.”
Kautzky-Willer, A., & Lemmens-Gruber, R. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-30726-3_15 · Cited by 4
“This may be ascribed to inhibition of carbohydrate absorption, but also to augmentation of incretin hormone release and effects on gut microbiota flora (Defronzo and Abdul-Ghani 2011).”
BackgroundQian, J., Thomas, A. P., Schroeder, A., Rakshit, K., Colwell, C. S., & Matveyenko, A. V. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00406.2016 · Cited by 4
Lee, Y. K., Oh, T. J., Lee, J. I., Choi, B. Y., Cho, H. C., Jang, H. C., & Choi, S. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175946 · Cited by 4
Modeling the cumulative benefits of regular physical activity on type 2 diabetes progression
Paola, P. F. D., Borri, A., Dabbene, F., Keshavjee, K., Palumbo, P. J., & Paglialonga, A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111194 · Cited by 10
Li, G., Chen, X., Liang, X., Hu, L., Zhang, L., Xu, X., Wu, W., Huang, K., Dong, G., Zhang, J., et al. (2019) · Pediatric Diabetes · doi:10.1111/pedi.12905 · Cited by 4
β-Cell function during a high-fat meal in young versus old adults: role of exercise
Malin, S. K., Frick, H., Wisseman, W. S., Edwards, E. S., Edwards, D. A., Emerson, S. R., & Kurti, S. P. (2023) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00047.2023 · Cited by 5
Trace glucose fluxes in individuals with prediabetes using stable isotopes
Du, S., Xia, F., Xu, X., Zhang, H., Zhu, C., & Lu, Y. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20140001 · Cited by 4
“While some investigators argue that metformin is the ideal choice for intervention of prediabetes and initial treatment of T2DM because of its ability to amelioration insulin resistance,(20) others feel that medications providing beta cell rest and possible restoration of beta cell function are preferable.(21) However…”
BackgroundAYDIN, A., Atadağ, Y. B., Öksüz, A., Kaya, D. G., & Aydın, N. E. (2017) · Journal of Surgery and Medicine · doi:10.28982/josam.337791 · Cited by 4
Mittendorfer, B., Patterson, B. W., Magkos, F., Yoshino, M., Bradley, D. P., Eagon, J. C., & Klein, S. (2023) · JCI Insight · doi:10.1172/jci.insight.170307 · Cited by 4
“In fact, the severity of β cell dysfunction is the major determinant of developing T2D rather than prediabetes because insulin resistance is often not different between people with prediabetes and T2D (2, 3).”
Obafemi, T. O., Alfa, J. A., Obafemi, B. A., Jaiyesimi, K. F., Olasehinde, O. R., Adewale, O. B., Akintayo, C. O., & Adu, I. A. (2023) · Comparative Clinical Pathology · doi:10.1007/s00580-023-03528-4 · Cited by 5
Li, Y. M., Zhang, L. H., Li, X. J., Zhang, B., Hou, J. N., & Tong, N. W. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00799-w · Cited by 5
“on preservation of beta cell function [5], about 50–80% of beta cell function may have decreased by the time diabetes is diagnosed.”
BackgroundKabadi, U. M. (2013) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2013.33019 · Cited by 6
Kim, Y., Ha, J., & Moon, J. S. (2026) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2026.0034 · Cited by 8
“…combining basal insulin, metformin, and incretin-based agents or SGLT2 inhibitors, often with structured life-style support, have reported remission rates ranging from 17% to 68% at 6 to 12 months post-therapy cessation, with outcomes correlating closely to baseline β-cell function [89,121-125].”
Kanter, M. M., Aaron, S., Austad, S. N., Brown, A. W., Burd, N. A., Campbell, W. W., Cope, M. B., Davis, T. A., Erdman, J. W., Freitas, M., et al. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2658728 · Cited by 7
“Accordingly, interventions that increase insulin sensitivity (i.e., reduce insulin resistance) lower the demand on the pancreatic beta-cells, thus preventing or slowing beta-cell exhaustion and dysfunction, which can prevent or treat cardiometabolic diseases (Defronzo and Abdul-Ghani 2011).”
Doi, S. A. R., & Ward, G. M. (2014) · Endocrine · doi:10.1007/s12020-014-0284-0 · Cited by 3
Valle, M. M. R., Vilas‐Boas, E. A., Lucena, C. F., Teixeira, S. A., Muscará, M. N., & Carpinelli, Â. R. (2022) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23007 · Cited by 3
Balducci, S., Haxhi, J., Vitale, M., Mattia, L., Bollanti, L., Conti, F., Cardelli, P., Sacchetti, M., Orlando, G., Zanuso, S., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110140 · Cited by 5
Swain, J., Jadhao, P. A., Sravya, S. L., Teli, B. R., Lavanya, K., Singh, J., Sahoo, A., & Das, S. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575260225230921062013 · Cited by 7
Rathor, S., Singh, S., Sharma, N., Zahoor, I., & Bhyan, B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13587-3.00012-6 · Cited by 3
Pancreatic β‐cell Function is Higher in Morning Versus Intermediate Chronotypes With Obesity
Malin, S. K., Remchak, M. E., Heiston, E. M., Fabris, C., & Shah, A. M. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70064 · Cited by 3
“However, improving β‐cell function to secrete insulin relative to low skeletal muscle, liver and/or adipose insulin sensitivity is critical to promote glycemic control [4].”
García-Vallvé, S., Guasch, L., & Mulero, M. (2014) · Springer eBooks · doi:10.1007/978-3-319-10226-9_6 · Cited by 3
Metadata
- Authors
- DeFronzo, R. A., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- DeFronzo, Ralph A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-08
- Volume
- 96
- Issue
- 8
- Pages
- 2354-2366
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2131616886
- Cited by
- 247
- References
- 131
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 7 · 2021: 11 · 2020: 23 · 2019: 12 · 2018: 18 · 2017: 16 · 2016: 19 · 2015: 14 · 2014: 31 · 2013: 28 · 2012: 17
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, impaired glucose tolerance, beta-cell preservation, insulin resistance, thiazolidinediones, metformin, glucagon-like peptide-1 analogues, acarbose, lifestyle modification, pharmacological interventions, prediabetes
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Prediabetic State, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.